Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice

Psychopharmacology

Volumn 228, Issue 3, 2013, Pages 401-409

  Gamble George, Joyonna C ^a,b   Conger, Jordan R ^a,b   Hartley, Nolan D ^a,b   Gupta, Prerna ^a,b   Sumislawski, Joshua J ^a,b   Patel, Sachin ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anorexia; Anxiety; Cannabinoid; CB1 receptor; CB2 receptor; Depression; Endocannabinoid; Rimonabant; SR144528; Stress

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG MECHANISM; FEEDING BEHAVIOR; GROOMING; HYPOPHAGIA; JUVENILE ANIMAL; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCRATCHING; TREATMENT RESPONSE;

ANIMALS; ANXIETY; CANNABINOID RECEPTOR ANTAGONISTS; CONSUMMATORY BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING DISORDERS; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; STRESS, PSYCHOLOGICAL;

EID: 84880262724     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3042-8     Document Type: Article

References (66)

1. Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585-1614, Abingdon, England
2. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106
3. Betancur C, Dell'Omo G, Alleva E (1994) Magnetic field effects on stress-induced analgesia in mice: modulation by light. Neurosci Lett 182:147-150
4. Chhatwal JP, Ressler KJ (2007) Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectr 12:211-220
5. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713
6. Cota D, Tschop MH, Horvath TL, Levine AS (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85-107
7. Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589
8. Droste SM, Saland SK, Schlitter EK, Rodefer JS (2010) AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav 95:443-448
9. Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771-783
10. Fattore L, Melis M, Fadda P, Pistis M, Fratta W (2010) The endocannabinoid system and nondrug rewarding behaviours. Exp Neurol 224:23-36
11. Fernandez-Espejo E, Caraballo I, de Fonseca FR, El Banoua F, Ferrer B, Flores JA, Galan-Rodriguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18:591-601
12. Gardner EL (2011) Addiction and brain reward and antireward pathways. Adv Psychosom Med 30:22-60
13. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363
14. Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261-267
15. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, Martin BR, Abood ME (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377:117-125
16. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395-1398
17. Haller J, Varga B, Ledent C, Barna I, Freund TF (2004) Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19:1906-1912
18. Haring M, Grieb M, Monory K, Lutz B, Moreira FA (2013) Cannabinoid CB(1) receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations. Neuropharmacology 65:83-89
19. Hernandez G, Cheer JF (2012) Effect of CB1 receptor blockade on food-reinforced responding and associated nucleus accumbens neuronal activity in rats. J Neurosci 32:11467-11477
20. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS (2010) Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 30:14980-14986
21. Jarbe TU, Ross T, DiPatrizio NV, Pandarinathan L, Makriyannis A (2006) Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 85:243-252
22. Johnson BA (1990) Psychopharmacological effects of cannabis. Br J Hosp Med 43: 114-6, 118-20, 122
23. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81
24. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2010) Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21-27
25. Kirkham TC, Tucci SA (2006) Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 5:272-292
26. Lopez HH (2010) Cannabinoid-hormone interactions in the regulation of motivational processes. Horm Behav 58:100-110
27. Lutz B (2009) Endocannabinoid signals in the control of emotion. Curr Opin Pharmacol 9:46-52
28. Mahler SV, Smith KS, Berridge KC (2007) Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32:2267-2278
29. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232
30. Mathes CM, Ferrara M, Rowland NE (2008) Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. Am J Physiol 295:R67-R75
31. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61-70
32. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496
33. Nelson K, Walsh D, Deeter P, Sheehan F (1994) A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10:14-18
34. Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S, Tolon RM, Romero J (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53:208-213, New York, NY
35. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514-536
36. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Liu QR, Chirwa SS, Hope B, Lujilde J, Inada T, Iwasaki S, Macharia D, Teasenfitz L, Arinami T, Uhl GR (2008) Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 1139:434-449
37. Osei-Hyiaman D (2007) Endocannabinoid system in cancer cachexia. Curr Opin Clin Nutr Metab Care 10:443-448
38. Pagotto U, Vicennati V, Pasquali R (2005) The endocannabinoid system and the treatment of obesity. Ann Med 37:270-275
39. Parolaro D, Vigano D, Rubino T (2005) Endocannabinoids and drug dependence. Curr Drug Targets 4:643-655
40. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304-311
41. Patel S, Hillard CJ (2008) Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci 27:2821-2829
42. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431-5438
43. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189-261
44. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG (1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40:695-700
45. Poncelet M, Maruani J, Calassi R, Soubrie P (2003) Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 343:216-218
46. Riebe CJ, Pamplona F, Kamprath K, Wotjak CT (2012) Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 204:159-185. doi: 10.1016/j.neuroscience.2011.11.057
47. Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91:383-388
48. Sciolino NR, Zhou W, Hohmann AG (2011) Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64(3):226-234. doi: 10.1016/j.phrs.2011.04.010
49. Serrano A, Parsons LH (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132:215-241
50. Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14:573-582
51. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831
52. Sumislawski JJ, Ramikie TS, Patel S (2011) Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 36:2750-2761
53. Sykes SM, Henton WW (1982) Control of wheel running by near-ultraviolet light. Physiol Behav 29:965-970
54. Tallett AJ, Blundell JE, Rodgers JR (2007a) Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behav Pharmacol 18:591-600
55. Tallett AJ, Blundell JE, Rodgers RJ (2007b) Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology (Berl) 195:27-39
56. Thornton-Jones ZD, Vickers SP, Clifton PG (2005) The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl) 179:452-460
57. Thornton-Jones ZD, Kennett GA, Vickers SP, Clifton PG (2007) A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour. Psychopharmacology (Berl) 193:1-9
58. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544-553
59. Verty AN, McGregor IS, Mallet PE (2004) Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 354:217-220
60. Vickers SP, Kennett GA (2005) Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 6:215-223
61. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M (2007) Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast: 52908
62. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, Martin BR (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293-300
63. Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13:225-238
64. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A (2005) Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29:358-367
65. Wright FL, Rodgers RJ (2012) Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology (Berl) 226(2):415-431. doi: 10.1007/s00213-012-2916-5
66. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL (2011) Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci 14:1160-1166